Analyst updates cardiology market from East Coast session

By Lisa Kerner

Erie, Pa., Feb. 27 - Bear Stearns recently held its cardiology due diligence session at a major East Coast hospital. Analyst Rick Wise summarized key takeways related to the drug-eluting stent (DES) and cardiac rhythm management (CRM) markets, including:

• CRM market - Overall high-energy implant volumes for implantable cardiac defibrillators and cardiac resynchronization therapy implant procedures are relatively flat. Growth is possibly shifting to community hospitals.

• DES market - New generation of stents were reviewed, with Guidant Corp.'s Xcience, Johnson and Johnson's Cypher NXT and Abbott Laboratories' Zomaxx stent platforms of particular interest.

• Peripheral markets - Endovascular procedures are growing rapidly at hospitals, with endovascular procedures growing as the technology improves. Of all the key devices the hospital uses now, only one was available 15 years ago.

• Percutaneous heart valve procedures could have a big impact on regular valve implants within the next five years. The physician thinks patients will be willing to accept the loss of ideal effectiveness of the current valve technology for less-invasive percutaneous heart valves.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.